At-Home Microneedling of Acral Skin to Increase Percutaneous Absorption of Imiquimod

Main Article Content

Kate Beekman
USF Health Morsani College of Medicine

Danielle DePalo
James Grichnik
Lilia Correa
Jonathan Zager

Keywords

Microneedling, acral skin, melanoma, acral lentiginous melanoma, melanoma in situ, malignant melanoma in situ, MMIS, skin cancer, imiquimod, topicals, curettage

References

1. Nakamura Y, Fujisawa Y. Diagnosis and Management of Acral Lentiginous Melanoma. Curr Treat Options Oncol. 2018;19(8):42. Published 2018 Jun 27. doi:10.1007/s11864-018-0560-y

2. Pandit AS, Geiger EJ, Ariyan S, Narayan D, Choi JN. Using topical imiquimod for the management of positive in situ margins after melanoma resection. Cancer Med. 2015;4(4):507-12. Epub 20150126. doi: 10.1002/cam4.402. PubMed PMID: 25620351; PubMed Central PMCID: PMC4402064.

3. Al-Mayahy MH, Sabri AH, Rutland CS, et al. Insight into imiquimod skin permeation and increased delivery using microneedle pre-treatment. Eur J Pharm Biopharm. 2019;139:33-43. doi: 10.1016/j.ejpb.2019.02.006

Article Sidebar

PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.2.17

Article Details

How to Cite
Beekman, K., DePalo, D., Grichnik, J., Correa, L., & Zager, J. (2023). At-Home Microneedling of Acral Skin to Increase Percutaneous Absorption of Imiquimod. SKIN The Journal of Cutaneous Medicine, 7(2), 743–744. https://doi.org/10.25251/skin.7.2.17
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Compelling Comments
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.